Doctors warn GLP-1 weight-loss drugs may fuel eating disorders

GLP-1 weight-loss drugs have become a clinical success story and a clinical concern at the same time. Their appetite-suppressing power can improve weight and cardiometabolic health, but doctors are also seeing how that same effect can intersect with dieting pressure, body-image distress, and a return of restrictive behavior in vulnerable patients.

A fast-moving shift in obesity care

The scale of GLP-1 use helps explain why the conversation has changed so quickly. A U.S. analysis found that starts of GLP-1 receptor agonists among people without diabetes but with overweight or obesity climbed from about 21,000 in 2019 to more than 174,000 in 2023, a jump of more than 700%. That kind of growth has pushed these drugs far beyond a narrow endocrinology niche and into everyday primary care, obesity medicine, and mental-health screening.

That expansion also changes the risk profile. When a medication becomes common, the question is no longer only whether it works, but how it behaves in the real world, among patients with different histories, motivations, and vulnerabilities. For GLP-1s, the concern is not that they are inherently dangerous; it is that powerful appetite suppression can amplify obsessive weight-control behavior in people already prone to disordered eating.

Who is most at risk

The clearest red flags involve patients with active eating disorders, a past eating-disorder history, or a high susceptibility to developing one. The National Eating Disorders Association says GLP-1 medications are of particular concern in exactly those groups, especially because the drugs can increase fullness and produce significant, sometimes rapid, weight loss.

That matters because rapid change itself can be destabilizing. In patients with a history of restriction, purging, or compulsive weight checking, a drug that makes eating feel easier to skip can become part of a relapse pattern rather than a metabolic tool. The risk is also heightened when the main goal is cosmetic weight loss instead of treatment for obesity complicated by diabetes, cardiovascular risk, or other medical problems.

What doctors are watching for

Clinicians are not looking for one single warning sign. They are watching for a cluster of behaviors that suggest the treatment is crossing from medical management into compulsion, including relentless dose escalation, fixation on rapid weight loss, skipping meals, anxiety around eating, and the reappearance of restrictive habits in someone with a prior disorder.

These signals can be subtle at first. A patient who praises appetite loss may actually be moving toward undernutrition, social withdrawal, or a distorted sense that any weight loss, no matter how fast, is success. That is why the clinical conversation has broadened from weight and glucose alone to include nutrition, mood, and behavior.

What the field is saying now

Professional and advocacy groups are moving toward a more cautious posture. The National Eating Disorders Association says GLP-1 use deserves special concern in people with active illness, past illness, or strong susceptibility, and recent advisory work by the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society goes further.

That joint advisory says people with a history of eating disorder who are considering GLP-1s for obesity should be referred to both an obesity medicine specialist and an eating disorders specialist. It also says restrictive eating disorder is a general contraindication to GLP-1 use. In practical terms, that is a sign the field is no longer treating this as a vague theoretical worry. It is becoming part of prescribing norms.

Why the evidence is still thin

Even with growing caution, the evidence base remains incomplete. Recent reviews say the psychological and behavioral effects of GLP-1 drugs, especially in relation to eating disorders, are still insufficiently understood. That leaves clinicians in a difficult position: they can see the metabolic benefits clearly, but they do not yet have a robust map of how these drugs affect body image, compulsive behavior, or relapse risk over time.

There is also a structural gap in care. Experts have noted that widely accepted clinical practice guidelines for screening, assessing, and monitoring eating-disorder risk in obesity treatment settings are still lacking. That makes prescribing more variable from one clinic to the next, and it raises the odds that warning signs will be missed unless clinicians ask directly and follow up carefully.

What safer prescribing looks like

The safest approach is less about avoiding GLP-1s altogether and more about using them with better guardrails. Before prescribing, clinicians should screen for eating-disorder history, ask about current restrictive behaviors, and discuss whether the patient is seeking weight loss for health reasons or for appearance-driven goals. Clear expectations matter: the treatment plan should define success in terms of health markers, nutrition, and function, not just the number on the scale.

Follow-up should be equally deliberate. Useful monitoring includes:

• appetite changes and meal skipping
• rising anxiety around food or eating in public
• overfocus on dose increases or speed of weight loss
• changes in mood, body checking, or social withdrawal
• signs of undernutrition or relapse in patients with prior disorder

That monitoring has to be paired with realistic counseling. The FDA-approved Wegovy prescribing information says semaglutide is used with a reduced-calorie diet and increased physical activity, and it also carries a boxed warning about thyroid C-cell tumors. The larger point is that GLP-1 therapy is meant to sit inside a broader medical plan, not replace it.

Regulators are still watching closely

The safety debate around GLP-1s extends beyond eating behavior. In January 2026, the FDA said its preliminary evaluation did not suggest a causal link between GLP-1 receptor agonists and suicidal thoughts or actions, and it asked manufacturers to remove that warning language from certain labels. At the same time, the agency continues to monitor postmarketing safety through systems such as the FDA Adverse Event Reporting System and Sentinel.

That regulatory stance is important because it shows the class is still being watched in real time as use expands. The agency’s review does not settle every mental-health question around GLP-1s, but it does reinforce a broader reality: these drugs affect appetite, weight, and behavior at scale, so safety oversight has to keep pace with uptake.

The clinical dilemma is no longer whether GLP-1s can help patients lose weight. It is whether prescribers can separate careful medical use from a broader culture of restriction, and whether vulnerable patients can be identified before appetite suppression becomes a trigger for disorder.